Literature DB >> 17942756

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Josh Lauring1, Abde M Abukhdeir, Hiroyuki Konishi, Joseph P Garay, John P Gustin, Qiuju Wang, Robert J Arceci, William Matsui, Ben Ho Park.   

Abstract

Multiple myeloma (MM) is an incurable hematologic malignancy characterized by recurrent chromosomal translocations. Patients with t(4;14)(p16;q32) are the worst prognostic subgroup in MM, although the basis for this poor prognosis is unknown. The t(4;14) is unusual in that it involves 2 potential target genes: fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET). MMSET is universally overexpressed in t(4;14) MM, whereas FGFR3 expression is lost in one-third of cases. Nonetheless, the role of MMSET in t(4;14) MM has remained unclear. Here we demonstrate a role for MMSET in t(4;14) MM cells. Down-regulation of MMSET expression in MM cell lines by RNA interference and by selective disruption of the translocated MMSET allele using gene targeting dramatically reduced colony formation in methylcellulose but had only modest effects in liquid culture. In addition, MMSET knockdown led to cell-cycle arrest of adherent MM cells and reduced the ability of MM cells to adhere to extracellular matrix. Finally, MMSET knockdown and knockout reduced tumor formation by MM xenografts. These results provide the first direct evidence that MMSET plays a significant role in t(4;14) MM and suggest that therapies targeting this gene could impact this particular subset of poor-prognosis patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942756      PMCID: PMC2200833          DOI: 10.1182/blood-2007-05-088674

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.

Authors:  Heidi Rye Hudlebusch; Kim Theilgaard-Mönch; Marianne Lodahl; Hans Erik Johnsen; Thomas Rasmussen
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.

Authors:  Adam D Judge; Vandana Sood; Janet R Shaw; Dianne Fang; Kevin McClintock; Ian MacLachlan
Journal:  Nat Biotechnol       Date:  2005-03-20       Impact factor: 54.908

3.  Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.

Authors:  Michela Mattioli; Luca Agnelli; Sonia Fabris; Luca Baldini; Fortunato Morabito; Silvio Bicciato; Donata Verdelli; Daniela Intini; Lucia Nobili; Lilla Cro; Giancarlo Pruneri; Vincenzo Callea; Caterina Stelitano; Anna Teresa Maiolo; Luigia Lombardi; Antonino Neri
Journal:  Oncogene       Date:  2005-04-07       Impact factor: 9.867

4.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

5.  Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.

Authors:  Lijun Zhu; George Somlo; Bingsen Zhou; Jimin Shao; Victoria Bedell; Marilyn L Slovak; Xiyong Liu; Jianhong Luo; Yun Yen
Journal:  Mol Cancer Ther       Date:  2005-05       Impact factor: 6.261

6.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

Authors:  M Chesi; P L Bergsagel; O O Shonukan; M L Martelli; L A Brents; T Chen; E Schröck; T Ried; W M Kuehl
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

7.  WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma.

Authors:  I Stec; T J Wright; G J van Ommen; P A de Boer; A van Haeringen; A F Moorman; M R Altherr; J T den Dunnen
Journal:  Hum Mol Genet       Date:  1998-07       Impact factor: 6.150

8.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Authors:  M Chesi; E Nardini; R S Lim; K D Smith; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

Review 9.  Advances in biology of multiple myeloma: clinical applications.

Authors:  Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

10.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Authors:  Elaine M Hurt; Adrian Wiestner; Andreas Rosenwald; A L Shaffer; Elias Campo; Tom Grogan; P Leif Bergsagel; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2004-02       Impact factor: 31.743

View more
  73 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

2.  "Snorkeling" for missing players in cancer.

Authors:  Riccardo Taulli; Pier Paolo Pandolfi
Journal:  J Clin Invest       Date:  2012-07-02       Impact factor: 14.808

3.  Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Authors:  Ping Yang; Linlang Guo; Zhijian J Duan; Clifford G Tepper; Ling Xue; Xinbin Chen; Hsing-Jien Kung; Allen C Gao; June X Zou; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

4.  Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.

Authors:  Yupeng Zheng; Luca Fornelli; Philip D Compton; Seema Sharma; Jesse Canterbury; Christopher Mullen; Vlad Zabrouskov; Ryan T Fellers; Paul M Thomas; Jonathan D Licht; Michael W Senko; Neil L Kelleher
Journal:  Mol Cell Proteomics       Date:  2015-08-13       Impact factor: 5.911

5.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

Authors:  Eva Martinez-Garcia; Relja Popovic; Dong-Joon Min; Steve M M Sweet; Paul M Thomas; Leonid Zamdborg; Aaron Heffner; Christine Will; Laurence Lamy; Louis M Staudt; David L Levens; Neil L Kelleher; Jonathan D Licht
Journal:  Blood       Date:  2010-10-25       Impact factor: 22.113

Review 6.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

Review 7.  Protein methyltransferases as a target class for drug discovery.

Authors:  Robert A Copeland; Michael E Solomon; Victoria M Richon
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

8.  Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma.

Authors:  Peng Zhou; Lie-Lin Wu; Ke-Min Wu; Wei Jiang; Jin-Dong Li; Le-du Zhou; Xin-Ying Li; Shi Chang; Yun Huang; Hui Tan; Ge-Wen Zhang; Feng He; Zhi-Ming Wang
Journal:  Pathol Oncol Res       Date:  2012-12-08       Impact factor: 3.201

9.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

Authors:  Jotin Marango; Manabu Shimoyama; Hitomi Nishio; Julia A Meyer; Dong-Joon Min; Andres Sirulnik; Yolanda Martinez-Martinez; Marta Chesi; P Leif Bergsagel; Ming-Ming Zhou; Samuel Waxman; Boris A Leibovitch; Martin J Walsh; Jonathan D Licht
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

10.  MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

Authors:  Jose L R Brito; Brian Walker; Matthew Jenner; Nicholas J Dickens; Nicola J M Brown; Fiona M Ross; Athanasia Avramidou; Julie A E Irving; David Gonzalez; Faith E Davies; Gareth J Morgan
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.